Top Injectable Manufacturer in Papua New Guinea – Reliable Pharmaceutical Solutions
- Maulik Sudani
- 3 days ago
- 9 min read
Last Updated: August 23, 2026
TL;DR: Papua New Guinea regulates medicines through the Pharmaceutical Services Standards Branch (PSSB) of the National Department of Health, which administers the Medicines and Cosmetics Act 1999 and reviews products through a marketing authorization system launched with WHO support in August 2019; a Draft Medicines Bill was under review as of August 2025, following a 2024 WHO Global Benchmarking assessment that made Papua New Guinea the first Pacific Island Country to begin formal CAPA planning — though we could not confirm a published numeric GBT maturity level or PIC/S application for PSSB and have not stated one here. Papua New Guinea does not appear among the 130 Contracting Parties on the HCCH's official 1961 Apostille Convention status table, so Certificates of Pharmaceutical Product and GMP certificates from India require full consular/embassy legalization rather than apostille. Public medicine supply runs through regional Area Medical Stores that have long struggled with stock continuity, and international partners fill much of the gap: Australia's DFAT invests over $100 million a year in the health sector, the Global Fund has approved roughly US$187 million in cumulative grants since 2004, and the World Bank and WHO co-fund national TB and regulatory-strengthening programs. WHO classifies Papua New Guinea as highly endemic for tuberculosis based on 2019 estimates, with Daru in Western Province a recognized global MDR-TB hotspot, while the country alone accounted for 87.5% of malaria cases in the WHO Western Pacific Region in 2023. Farbe Firma, a WHO-GMP certified sterile injectable manufacturer in Gujarat, India producing 100+ injectable products under ISO Class 5 aseptic conditions and exporting to 30+ countries, supports Papua New Guinean importers and institutional buyers with CTD/ACTD-ready documentation mapped to PSSB's registration requirements.
Key Takeaways
The Pharmaceutical Services Standards Branch (PSSB), within Papua New Guinea's National Department of Health, administers the Medicines and Cosmetics Act 1999 and its 2002 Regulation, registers products through the marketing authorization system launched with WHO support in August 2019, and licenses importers, wholesalers and distributors through its Compliance Licensing & Inspecting unit. PSSB also runs the country's own Medicine Quality Control Laboratory, opened in 2017, and a Draft Medicines Bill was under active technical review as of August 2025. We could not confirm that PSSB has formally adopted the ICH Common Technical Document as its required dossier format, so Farbe Firma prepares its files in CTD/ACTD format and maps them to PSSB's registration and GMP-clearance checklists.
PSSB underwent a WHO Global Benchmarking Tool assessment in 2024, producing an Institutional Development Plan and, by August 2025, making Papua New Guinea the first Pacific Island Country to begin formal CAPA planning — but we could not confirm a published numeric GBT maturity level or PIC/S application for PSSB and have not stated one here. Public medicine supply runs through regional Area Medical Stores that have long struggled with stock continuity, and NDoH's own procurement function has faced documented governance challenges historically. International partners now carry much of the structural weight: DFAT invests over $100 million a year in the health sector and funds the AU$200 million PNG-Australia Transition to Health program (2020–2025), the Global Fund has approved roughly US$187 million in grants since 2004, and the World Bank, Asian Development Bank, UNFPA and WHO each fund distinct pieces of the system.
Papua New Guinea does not appear among the 130 Contracting Parties on the HCCH's official 1961 Apostille Convention status table, meaning it is not a Convention member. Certificates of Pharmaceutical Product, GMP certificates and other documents issued in India for use here therefore require full consular/embassy legalization rather than the faster apostille process several other markets in this series enjoy — a longer documentation timeline Farbe Firma's regulatory team builds into every Papua New Guinea-bound registration from the outset.
WHO classifies Papua New Guinea as highly endemic for tuberculosis (2019 estimates place incidence in the 300–499-per-100,000 band), and the country remains on both the 2021–2025 high TB burden and high MDR/RR-TB burden lists; Western Province recorded a 674-per-100,000 notification rate in 2016, and Daru, its capital, is a WHO-recognized global MDR-TB hotspot, with drug-resistant TB prevalence near 3% among new cases and 26% among retreatment cases. Malaria places the country in a category of its own — WHO attributes 87.5% of cases and nearly 92% of deaths across the Western Pacific Region in 2023 to Papua New Guinea alone — and a maternal mortality ratio near 189 per 100,000 live births keeps obstetric injectables essential too.
Introduction: Why an Injectable Manufacturer in Papua New Guinea Must Meet Global Standards Across a Fragmented Supply Chain
Papua New Guinea, home to roughly 10.8 million people across a mainland and hundreds of islands, is one of the most structurally distinctive markets in this series: WHO classifies it as highly endemic for tuberculosis, malaria alone accounts for most of the WHO Western Pacific Region's case and death burden, and much of the medicine supply chain depends on donor funding rather than domestic procurement alone. Any credible injectable manufacturer in Papua New Guinea must work within PSSB's registration pathway while understanding that its buyers — the National Department of Health, provincial health authorities, and the donor-funded programs supporting them — operate inside a supply chain that has long struggled to keep rural facilities consistently stocked.
Farbe Firma Pvt Ltd, operating from Gujarat, India as a WHO-GMP certified sterile injectable manufacturer, produces more than 100 injectable formulations inside ISO Class 5 aseptic filling suites and exports to more than 30 countries under CTD and ACTD dossier formats. Serving Papua New Guinea well means preparing documentation PSSB can review efficiently, understanding that its absence from the Hague Apostille Convention means certificates require full consular legalization, and recognizing that institutional demand often flows through donor-backed procurement channels as much as government tenders. Farbe Firma builds its Papua New Guinea engagement around all three realities at once.
What Sets a World-Class Injectable Manufacturer in Papua New Guinea Apart
Any credible injectable manufacturer in Papua New Guinea has to work through PSSB's marketing authorization system, launched with WHO support in August 2019, which requires evidence of GMP-compliant manufacturing, non-clinical and clinical safety and efficacy data, and complete product information before the NDoH Pharmacy Board issues a Marketing Authorisation Certificate. Import, wholesale, export and distribution activity is separately licensed through PSSB's Compliance Licensing & Inspecting unit, and every batch entering the country falls under the oversight of Papua New Guinea's own Medicine Quality Control Laboratory, opened in Port Moresby in 2017. Farbe Firma works closely with its import partners to keep licensing and product dossiers aligned from the start.
Beyond registration, winning institutional business means understanding a procurement landscape shaped as much by development partners as by government. Public medicine supply moves through regional Area Medical Stores — the Lae store alone supplies close to 200 facilities across Morobe and four neighbouring provinces — while major disease programs are underwritten by Australia's PATH program, Global Fund grants, and a World Bank-funded Emergency Tuberculosis Project. Suppliers who can document consistent batch-to-batch quality and realistic delivery commitments earn trust in a system where past procurement governance problems have made partners cautious about undocumented new suppliers — exactly the track record Farbe Firma has built exporting to more than 30 countries.
Quality Systems Behind Every Batch We Ship to Papua New Guinea
Every batch leaving Farbe Firma's Gujarat facility for Papua New Guinea passes through the same analytical panel we apply globally. Identity, assay and related-substance testing run on validated HPLC and GC methods benchmarked against USP, BP, IP and EP monographs, Karl Fischer titration confirms residual moisture in lyophilized and powder-fill products, and every sterile lot undergoes sterility testing and bacterial endotoxin (LAL) testing, alongside sub-visible particulate counts, pH, osmolality and fill-volume verification. This is the certificate-of-analysis and validation documentation PSSB reviewers expect within a marketing-authorization submission, and that Area Medical Store and donor-program evaluators typically request during procurement due diligence.
Stability data is generated under ICH Q1A(R2) long-term and accelerated conditions, with photostability assessed per ICH Q1B, so shelf-life claims hold up under Papua New Guinea's tropical climate and the realities of Area Medical Store distribution to facilities scattered across highlands and outer islands. Because Papua New Guinea is not a party to the Hague Apostille Convention, Farbe Firma routes Certificates of Pharmaceutical Product and GMP certificates through full consular/embassy legalization rather than apostille, and our regulatory team builds that longer timeline into every Papua New Guinea-bound registration from the outset.
Looking for a sterile injectable manufacturing partner? Submit a Quick Inquiry
Why Farbe Firma is the Trusted Injectable Manufacturer in Papua New Guinea for Global Buyers
Papua New Guinea's disease burden creates several overlapping streams of injectable demand. WHO classifies the country as highly endemic for tuberculosis and keeps it on both the 2021–2025 high TB burden and high MDR/RR-TB burden lists; Western Province recorded a 674-per-100,000 notification rate in 2016, and Daru, its capital, is a WHO-recognized global MDR-TB hotspot, with drug-resistant TB prevalence near 3% among new cases and 26% among retreatment cases. Malaria is, if anything, more concentrated: WHO attributes 87.5% of cases and nearly 92% of deaths across the Western Pacific Region in 2023 to Papua New Guinea alone, citing commodity stock-outs and unstable funding among the drivers — though a Global Fund-supported program evaluated over 2009–2014 cut measured parasite prevalence from about 12.1% to 1.8%. A maternal mortality ratio near 189 per 100,000 live births keeps uterotonics and other obstetric injectables essential nationwide.
Farbe Firma also functions as a CDMO/CMO partner for manufacturers and brand owners, offering private-label sterile injectables on the same WHO-GMP, ISO Class 5 platform, with CTD/ACTD-format files that map cleanly onto PSSB's requirements — documentation discipline that matters even more here, since institutional purchasing often flows through donor-funded mechanisms that apply their own supplier due diligence.
India's trade relationship with Papua New Guinea is real, if still modest at the pharmaceutical level: bilateral trade was reported at roughly USD 729.2 million in 2024–25 by India's High Commission in Port Moresby, and Papua New Guinea's pharmaceutical imports from India were valued at approximately US$29.28 million in 2023, supported by a bilateral MoU on Health Sector Cooperation signed in 2016. Papua New Guinea has little domestic pharmaceutical manufacturing capacity, so it depends on imports for the great majority of finished injectables — a gap established overseas manufacturers are well placed to fill. Succeeding here means treating PSSB registration, Area Medical Store and donor-procurement readiness, and full consular legalization as one integrated timeline, and Farbe Firma's export team builds every Papua New Guinea quote and delivery schedule around exactly that reality.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Is Farbe Firma a WHO-GMP certified injectable manufacturer for Papua New Guinea?
Yes. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer based in Gujarat, India, operating ISO Class 5 aseptic filling lines and producing more than 100 injectable products for export to over 30 countries. Our documentation is prepared in CTD and ACTD formats and mapped to the marketing-authorization and GMP-clearance requirements Papua New Guinea's Pharmaceutical Services Standards Branch (PSSB) reviews for product registration.
How does injectable product registration work in Papua New Guinea?
The Pharmaceutical Services Standards Branch (PSSB), within the National Department of Health, administers the Medicines and Cosmetics Act 1999 and its 2002 Regulation, and reviews pharmaceutical products through the marketing authorization system it launched in August 2019 in partnership with WHO. Registration requires evidence of GMP-compliant manufacturing, non-clinical and clinical safety and efficacy data, and complete product information before PSSB's Pharmacy Board issues a Marketing Authorisation Certificate; a Draft Medicines Bill was under active technical review as of August 2025 to strengthen this framework further.
Do we need a local importer or distributor to sell injectables in Papua New Guinea?
Yes. PSSB's Compliance Licensing & Inspecting unit issues the import, wholesale and distribution licenses required to bring pharmaceutical products into Papua New Guinea, and only registered establishments may deal in medicinal products. Because a large share of institutional volume moves through the Area Medical Store network and donor-funded procurement mechanisms such as the Global Fund and Australia's PNG-Australia Transition to Health program, a distributor's experience with those channels matters as much as its PSSB registration record.
Which injectables are in strongest demand in Papua New Guinea?
Demand is shaped by three overlapping burdens: anti-tuberculosis and drug-resistant-TB injectables, given WHO's classification of Papua New Guinea as highly endemic for TB and a recognized MDR-TB hotspot centered on Daru in Western Province; antimalarials and supportive-care injectables, since Papua New Guinea alone accounted for 87.5% of malaria cases in the WHO Western Pacific Region in 2023; and obstetric injectables such as uterotonics, given a maternal mortality ratio estimated near 189 per 100,000 live births. Farbe Firma's 100+ product range covers all three categories.
What documentation and logistics considerations matter most for a Papua New Guinea launch?
Papua New Guinea is not a party to the 1961 Hague Apostille Convention, so Certificates of Pharmaceutical Product, GMP certificates and other documents issued in India require full consular/embassy legalization rather than apostille — a longer process our regulatory team plans for from the outset. On the commercial side, expect distribution through the Area Medical Store network and a procurement landscape where donor-funded programs (Global Fund, DFAT, World Bank, WHO) sit alongside National Department of Health tenders, rather than a single centralized buying desk.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments